Cargando…

Post-operative ctDNA monitoring in stage I colon cancer: A case report

Circulating tumor DNA (ctDNA) level monitoring after surgery for colon cancer has been studied in stage II and III colon cancer to risk-stratify patients for adjuvant therapy. However, there is less data regarding the role of this diagnostic tool in the management of stage I disease, where current r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alden, Stephanie L., Dhani, Harmeet, Palsuledesai, Charuta C., Krinshpun, Shifra, Jurdi, Adham, Christenson, Eric, Browner, Ilene, Rosner, Samuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9795219/ https://www.ncbi.nlm.nih.gov/pubmed/36591529 http://dx.doi.org/10.3389/fonc.2022.1074786

Ejemplares similares

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
por: Azzi, Georges, et al.
Publicado: (2022)

ctDNA-based detection of molecular residual disease in stage I-III non-small cell lung cancer patients treated with definitive radiotherapy
por: Lebow, Emily S., et al.
Publicado: (2023)

Investigate the application of postoperative ctDNA-based molecular residual disease detection in monitoring tumor recurrence in patients with non-small cell lung cancer——A retrospective study of ctDNA
por: Zhang, Xuefei, et al.
Publicado: (2023)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC
por: Wang, Bolin, et al.
Publicado: (2023)

Assessing the Impact of Circulating Tumor DNA (ctDNA) in Patients With Colorectal Cancer: Separating Fact From Fiction
por: Gabriel, Emmanuel, et al.
Publicado: (2018)

Why the Therapeutic Impact of RAS Mutation Clearance in Plasma ctDNA Deserves to Be Further Explored in Metastatic Colorectal Cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2019)

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
por: Tan, Xiangyu, et al.
Publicado: (2021)

The Potential Use of Dynamics Changes of ctDNA and cfDNA in the Perioperative Period to Predict the Recurrence Risk in Early NSCLC
por: Zhao, Xiaolong, et al.
Publicado: (2021)

Circulating Tumor DNA as a Cancer Biomarker: An Overview of Biological Features and Factors That may Impact on ctDNA Analysis
por: Sánchez-Herrero, Estela, et al.
Publicado: (2022)

Frequent post-operative monitoring of colorectal cancer using individualised ctDNA validated by multiregional molecular profiling
por: Yaegashi, Mizunori, et al.
Publicado: (2021)

The Use of ctDNA in the Diagnosis and Monitoring of Hepatocellular Carcinoma—Literature Review
por: Kopystecka, Agnieszka, et al.
Publicado: (2023)

Potential value of ctDNA monitoring in metastatic HR + /HER2 − breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial
por: Chiu, Joanne, et al.
Publicado: (2023)

Next Generation Sequencing of Tumor and Matched Plasma Samples: Identification of Somatic Variants in ctDNA From Ovarian Cancer Patients
por: Barbosa, Ana, et al.
Publicado: (2021)

Role of ctDNA in Breast Cancer
por: Sant, Marta, et al.
Publicado: (2022)

The Role of ctDNA in Gastric Cancer
por: Mencel, Justin, et al.
Publicado: (2022)

Genomic landscape and survival analysis of ctDNA “neo-RAS wild-type” patients with originally RAS mutant metastatic colorectal cancer
por: Nicolazzo, Chiara, et al.
Publicado: (2023)

Utility of ctDNA Liquid Biopsies from Cancer Patients: An Institutional Study of 285 ctDNA Samples
por: Gumà, Josep, et al.
Publicado: (2022)

Pre-operative ctDNA predicts survival in high-risk stage III cutaneous melanoma patients
por: Lee, J H, et al.
Publicado: (2019)

The clinical utility of dynamic ctDNA monitoring in inoperable localized NSCLC patients
por: Yang, Yin, et al.
Publicado: (2022)

Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
por: Zhao, Jianhua, et al.
Publicado: (2023)

BESPOKE IO protocol: a multicentre, prospective observational study evaluating the utility of ctDNA in guiding immunotherapy in patients with advanced solid tumours
por: Kasi, Pashtoon Murtaza, et al.
Publicado: (2022)

Protein Prenylation: Enzymes, Therapeutics, and Biotechnology Applications
por: Palsuledesai, Charuta C., et al.
Publicado: (2014)

The Promise of Circulating Tumor DNA (ctDNA) in the Management of Early-Stage Colon Cancer: A Critical Review
por: Chakrabarti, Sakti, et al.
Publicado: (2020)

Blood, Toil, and Taxoteres: Biological Determinants of Treatment-Induced ctDNA Dynamics for Interpreting Tumor Response
por: Boniface, Christopher T., et al.
Publicado: (2022)

Characterization of genomic clones by targeted deep sequencing of ctDNA to monitor liver cancer
por: Sun, Yan, et al.
Publicado: (2021)

Case Report: Early detection of pancreatic pre-cancer lesion in multimodal approach with exosome liquid biopsy
por: Dhani, Harmeet, et al.
Publicado: (2023)

Corrigendum: Blood, toil, and taxoteres: Biological determinants of treatment-induced ctDNA dynamics for interpreting tumor response
por: Boniface, Christopher T., et al.
Publicado: (2023)

ctDNA Concentration, MIKI67 Mutations and Hyper-Progressive Disease Related Gene Mutations Are Prognostic Markers for Camrelizumab and Apatinib Combined Multiline Treatment in Advanced NSCLC
por: Chen, Yao, et al.
Publicado: (2020)

ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal–Anal Task Forces whitepaper
por: Dasari, Arvind, et al.
Publicado: (2020)

Individualized Mini-Panel Sequencing of ctDNA Allows Tumor Monitoring in Complex Karyotype Sarcomas
por: Braig, David, et al.
Publicado: (2022)

Liquid Biopsy, ctDNA Diagnosis through NGS
por: Lin, Chen, et al.
Publicado: (2021)

ctDNA as a biomarker of progression in oesophageal adenocarcinoma
por: Bonazzi, V.F., et al.
Publicado: (2022)

State of the Art: ctDNA in Upper Gastrointestinal Malignancies
por: Labiano, Ibone, et al.
Publicado: (2023)

Complementary Sequential Circulating Tumor Cell (CTC) and Cell-Free Tumor DNA (ctDNA) Profiling Reveals Metastatic Heterogeneity and Genomic Changes in Lung Cancer and Breast Cancer
por: Kong, Say Li, et al.
Publicado: (2021)

Detection and Quantification of ctDNA for Longitudinal Monitoring of Treatment in Non-Small Cell Lung Cancer Patients Using a Universal Mutant Detection Assay by Denaturing Capillary Electrophoresis
por: Benesova, Lucie, et al.
Publicado: (2022)

Phylogenetic ctDNA analysis depicts early stage lung cancer evolution
por: Abbosh, Christopher, et al.
Publicado: (2017)

The circulating tumor DNA (ctDNA) alteration level predicts therapeutic response in metastatic breast cancer: Novel prognostic indexes based on ctDNA
por: Liu, Binliang, et al.
Publicado: (2022)

Plasma ctDNA RAS mutation analysis for the diagnosis and treatment monitoring of metastatic colorectal cancer patients
por: Vidal, J, et al.
Publicado: (2017)

Assessing CSF ctDNA to Improve Diagnostic Accuracy and Therapeutic Monitoring in Breast Cancer Leptomeningeal Metastasis
por: Fitzpatrick, Amanda, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_vc6j250mogo58f5nrbos9fl9q3